Timokhin et al.
2-Meth yl-2-p h en ylsela n yl-3-(tolu en e-4-su lfon yl)-p r op i-
on ic a cid ter t-bu tyl ester (2d ) was prepared from 4d (116
mg, 0.816 mmol) and TsSePh. Column chromatography (EtOAc/
pentane, 0:100 to 10:90) gave 2d (88 mg, 0.194 mmol, 48%).
1H NMR: δ 1.39 (s, 9H), 1.67 (s, 3H), 2.34 (s, 3H), 3.48 (d, 1H,
J ) 13.8), 3.88 (d, 1H, J ) 13.8), 7.19-7.25 (m, 4H), 7.29-
7.36 (m, 1H), 7.46-7.49 (m, 2H), 7.66 (d, 2H, J ) 8.3). 13C
NMR: δ 22.0, 22.3, 28.1, 45.6, 65.3, 82.4, 126.7, 128.1, 129.5,
130.3, 130.4, 138.6, 138.8, 145.0, 170.8.
uents such as 2-naphthyl or carbamoyl exhibit the lowest
tendency to eliminate the tosyl radical as a result of
resonance stabilization.
Exp er im en ta l Section
Gen er a l. NMR spectra of CDCl3 solutions were recorded
at 300 MHz (1H) and 75 MHz (13C); J values are given in Hz.
Column chromatographies were performed on silica gel 60.
Initiators azobisisobutyronitrile, benzoyl and tert-butyl per-
oxides were commercially available and used without ad-
ditional purification. Pentamethylbenzene was used as inter-
nal standard for 1H NMR analysis of the crude product after
reaction. Tributyltin hydride was distilled and stored under
argon. Alkenes 4a , 4c, 4d , and 4e were commercially available
and used without additional purification. Amide 4b was
prepared from the appropriate acyl chloride2g and the corre-
sponding amine according to a standard procedure. TsBr and
TsSePh were prepared according to known procedures10,27 and
were dried under vacuum before use. Starting compounds 2
(bromides and phenylselenides) were synthesized by standard
methods 2a,10 and were purified by column chromatography on
silica gel. Spectral data for new compounds are listed below.
Gen er a l P r oced u r e for P r ep a r a tion of Br om o- or
P h en ylsela n yla lk yl Su lfon es (2). All reactions were carried
out under argon atmosphere. A solution of alkene 4 (1 mmol),
TsSePh (or TsBr) (1.3 mmol), and AIBN (0.13 mmol) in
degassed benzene (2 mL) was refluxed for 3-5 h (TLC
monitoring) (every 90 min additional portions of AIBN (5%)
were added). The solvent was evaporated, and the crude
product was purified by flash chromatography on silica gel
(EtOAc/pentane).
Ben zoic a cid 1-br om o-2-(tolu en e-4-su lfon yl)-eth yl es-
ter (2e) was prepared from 4e (105 mg, 0.709 mmol) and TsBr.
Column chromatography (EtOAc/pentane, 5:95 to 15:85) gave
1
2e (210 mg, 0.547 mmol, 77%). H NMR: δ 2.24 (s, 3H), 3.95
(dd, 1H, J ) 14.8, 1.5), 4.30 (dd, 1H, J ) 14.8, 10.4), 7.11-
7.18 (m, 3H), 7.35-7.43 (m, 2H), 7.56-7.61 (m, 1H), 7.67-
7.72 (m, 4H). 13C NMR: δ 21.9, 64.2, 67.0, 128.5, 128.8, 130.5,
130.6, 134.5, 136.3, 145.8, 163.3.
Gen er a l P r oced u r e for P r ep a r a tion of Red u ction
P r od u cts (5), a s Au th en tic Sa m p les. A solution of alkene
4 (1 mmol), TolSH (1.3 mmol) and AIBN (0.2 mmol) in
degassed benzene (2 mL) was refluxed for 3-5 h (TLC
monitoring) (every 90 min additional portions of AIBN (5%)
were added). The solvent was evaporated, the crude product
was dissolved in ethanol (10 mL) and cooled at 0°C, and then
a solution of Oxone (3.5 equiv) in water (9 mL) was added.
After stirring for 4 h, the mixture was diluted with water and
extracted three times with Et2O. The combined organic phases
were dried over sodium sulfate, concentrated, and purified by
flash chromatography (EtOAc/pentane).
1-P h en yl-3-(tolu en e-4-su lfon yl)-p r op a n e (5a ). Following
the general procedure, the title compound was prepared in 9%
yield. Column chromatography (EtOAc/pentane, 0:100 to 10:
90).1H NMR: δ 1.98-2.08 (m, 2H), 2.45 (s, 3H), 2.69 (t, 2H,
J ) 7.5), 3.03-3.08 (m, 2H), 7.09-7.11 (m, 2H), 7.17-7.29 (m,
3H), 7.34 (d, 2H, J ) 7.9), 7.76 (d, 2H, J ) 8.3). 13C NMR: δ
22.0, 24.7, 34.5, 55.9, 126.8, 128.5, 128.8, 129.0, 130.3, 136.5,
140.3, 145.0.
N ,N -D iis o p r o p y l-3-(t o lu e n e -4-s u lfo n y l)-p r o p io n a -
m id e (5b). Following the general procedure, the title com-
pound was prepared in 59% yield. Column chromatography
(EtOAc/pentane, 0:100 to 30:70).1H NMR: δ 1.19 (d, 6H, J )
6.8), 1.30 (d, 6H, J ) 6.8), 2.45 (s, 3H), 2.77-2.85 (m, 2H),
3.40-3.48 (m, 3H), 3.94 (sept, 1H, J ) 6.8), 7.36 (d, 2H, J )
8.3), 7.80 (d, 2H, J ) 8.3). 13C NMR: δ 20.5, 20.8, 21.6, 27.6,
45.9, 48.4, 52.2, 127.9, 129.9, 136.3, 144.8, 167.1.
1-[2-(Tolu en e-4-su lfon yl)-eth yl]-n a p h th a len e (5c). Fol-
lowing the general procedure, the title compound was prepared
in 65% yield. Column chromatography (EtOAc/pentane, 0:100
to 15:85).1H NMR: δ 2.41 (s, 3H), 3.16-3.21 (m, 2H), 3.40-
3.45 (m, 2H), 7.18-7.25 (m, 1H), 7.32 (d, 2H, J ) 7.9), 7.39-
7.46 (m, 2H), 7.52 (s, 1H), 7.70-7.78 (m, 3H), 7.81 (d, 2H, J )
8.1). 13C NMR: δ 22.0, 29.5, 57.9, 126.2, 126.7, 126.9, 127.2,
127.9, 128.0, 128.5, 128.9, 130.4, 132.7, 133.9, 135.3, 136.4,
145.2.
2-Meth yl-3-(tolu en e-4-su lfon yl)-p r op ion ic Acid ter t-
Bu tyl Ester (5d ). Following the general procedure, the title
compound was prepared in 64% yield. Column chromatography
(EtOAc/pentane, 0:100 to 10:90).1H NMR: δ 1.27 (d, 2H, J )
7.2), 1.40 (s, 9H), 2.44 (s, 3H), 2.82-2.93 (m, 1H), 3.00 (dd,
1H, J ) 14.3, 5.4), 3.65 (dd, 1H, J ) 14.2, 7.2), 7.36 (d, 2H,
J ) 7.9), 7.79 (d, 2H, J ) 8.3).13C NMR: δ 18.4, 22.0, 28.2,
36.0, 59.1, 81.7, 128.5, 130.3, 136.8, 145.2, 173.1.
Ben zoic a cid 2-(tolu en e-4-su lfon yl)-eth yl ester (5e) was
prepared as described in the literature.28 1H NMR: δ 2.35 (s,
3H), 3.59 (t, 2H, J ) 5.9), 4.65 (t, 2H, J ) 5.9), 7.26-7.29 (m,
2H), 7.33-7.38 (m, 2H), 7.45-7.64 (m, 1H), 7.70-7.73 (m, 2H),
7.81 (d, 2H, J ) 8.1). 13C NMR: δ 22.0, 55.7, 58.8, 128.5, 128.6,
128.9, 129.4, 130.0, 130.4, 130.6, 133.7, 134.1, 136.9, 145.3,
166.2.
1-P h en yl-2-br om o-3-(tolu en e-4-su lfon yl)-p r op a n e (2a )
was prepared from 4a (99 mg, 0.838 mmol) and TsBr. Column
chromatography (EtOAc/pentane, 0:100 to 10:90) gave 2a (266
1
mg, 0.754 mmol, 90%). H NMR: δ 2.44 (s, 3H), 3.17 (dd, 1H,
J ) 14.5, 8.3), 3.49 (dd, 1H, J ) 14.5, 5.1), 3.60-3.70 (AB part
of an ABX spectra, 2H, J AB ) 13.8), 4.45-4.55 (m, 1H), 7.18-
7.37 (m, 7H), 7.79 (d, 2H, J ) 8.3). 13C NMR: δ 22.1, 44.6,
45.2, 63.3, 127.7, 128.5, 129.0, 129.9, 130.5, 136.7, 137.1, 145.7.
1-P h en yl-2-p h en ylsela n yl-3-(t olu en e-4-su lfon yl)-p r o-
p a n e (2a ′) was prepared from 4a (119 mg, 1.003 mmol) and
TsSePh. Column chromatography (EtOAc/pentane, 0:100 to 10:
1
90) gave 2a ′ (373 mg, 0.869 mmol, 87%). H NMR: δ 2.41 (s,
3H), 3.05 (dd, 1H, J ) 14.4, 8.3), 3.35 (dd, 1H, J ) 14.4, 3.4),
3.42-3.51 (m, 2H), 3.61-3.72 (m, 1H), 7.12-7.33 (m, 12H),
7.62 (d, 2H, J ) 8.3). 13C NMR: δ 22.1, 38.5, 40.2, 60.7, 127.4,
128.3, 128.5, 128.9, 129.7, 129.9, 130.4, 135.1, 136.5, 138.3,
145.2.
N,N-Diisopr opyl-2-ph en ylselan yl-3-(tolu en e-4-su lfon yl)-
p r op ion a m id e (2b) was prepared from 4b (100 mg, 0.64
mmol) and TsSePh. Column chromatography (EtOAc/pentane,
1
1:99 to 25:75) gave 2b (230 mg, 0.49 mmol, 77%). H NMR: δ
1.14 (d, 3H, J ) 6.8), 1.22-1.29 (m, 9H), 2.39 (s, 3H), 3.34
(sept, 1H, J ) 6.8), 3.45 (d, 1H, J ) 12.7), 4.12 (sept, 1H, J )
6.6), 4.29-4.50 (m, 2H), 7.20-7.38 (m, 5H), 7.48-7.52 (m, 2H),
7.70 (d, 2H, J ) 8.2). 13C NMR: δ 20.0, 20.3, 20.9, 21.6, 33.5,
46.2, 49.4, 59.3, 126.3, 128.0, 129.1, 129.4, 129.7, 135.5, 135.6,
136.4, 144.6, 166.4.
1-[1-Br om o-2-(t olu e n e -4-su lfon yl)-e t h yl]-n a p h t h a -
len e (2c) was prepared from 4c (111 mg, 0.721 mmol) and
TsBr. Column chromatography (EtOAc/pentane, 0:100 to 20:
1
80) gave 2c (169 mg, 0.435 mmol, 60%). H NMR: δ 2.13 (s,
3H), 4.11 (dd, 1H, J ) 14.6, 5.0), 4.24 (dd, 1H, J ) 14.6, 9.9),
5.53 (dd, 1H, J ) 9.9, 5.0), 6.85 (d, 2H, J ) 8.1), 7.26 (dd, 1H,
J ) 8.2, 2.0), 7.37 (d, 2H, J ) 8.3), 7.44-7.50 (m, 2H), 7.58-
7.61 (m, 2H), 7.67-7.73 (m, 2H). 13C NMR: δ 21.7, 44.8, 64.2,
124.8, 127.0, 127.4, 127.44, 127.9, 128.3, 128.5, 129.3, 129.8,
133.1, 133.7, 135.8, 136.1, 145.1.
(27) Truce, W. E.; Heuring, D. L.; Wolf, G. C. J . Org. Chem. 1974,
39, 238-244.
(28) Miller, A. W.; Stirling, C. J . M. J . Chem. Soc. C 1962, 2612-
2617.
3536 J . Org. Chem., Vol. 68, No. 9, 2003